Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06311045
NA

Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)

Sponsor: NYU Langone Health

View on ClinicalTrials.gov

Summary

This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.

Official title: Basis of Sex-specific Therapeutic Responses to Obstructive Sleep Apnea (OSA): a Trial of N-acetylcysteine (NAC) in Obstructive Sleep Apnea (OSA)

Key Details

Gender

All

Age Range

55 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

14

Start Date

2024-05-07

Completion Date

2026-04

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

N-acetylcysteine (NAC)

Participants will take two NAC 600mg capsules daily for four weeks.

DIETARY_SUPPLEMENT

Placebo

Participants will take two placebo 600mg capsules daily for four weeks.

PROCEDURE

Positive Airway Pressure (PAP) Therapy

All participants will receive PAP therapy per standard of care for OSA.

Locations (1)

NYU Langone Health

New York, New York, United States